Boston Scientific to Acquire Preventice for ~$1.2B

 Boston Scientific to Acquire Preventice for ~$1.2B

Boston Scientific to Acquire Preventice for ~$1.2B

Shots:

  • Boston Scientific to acquire Preventice for ~$1.2B including $925M as up front, up to an additional $300M as commercial milestones. However, Boston Scientific has built up a 22% stake in Preventice, which is expected to lower up front to $720M upfront & $230 million in milestone respectively
  • The acquisition is expected to be close in mid-2021. The acquisition will add external cardiac monitoring technologies and services provider to Boston Scientific and expand its rhythm management diagnostics portfolio and capabilities
  • The Preventice portfolio includes the BodyGuardian family of remote, wearable cardiac monitors for adult and pediatric patients

Click here ­to­ read full press release/ article | Ref: Boston Scientific| Image: CRG

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post